[Pharmacology of Janus kinase inhibitors].
Pharmakologie der Januskinaseinhibitoren.
Autoimmune diseases
Cytokine receptors
Dermatotherapy
Inflammatory skin diseases
Safety profile
Journal
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
ISSN: 1432-1173
Titre abrégé: Hautarzt
Pays: Germany
ID NLM: 0372755
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
20
11
2019
medline:
4
12
2019
entrez:
20
11
2019
Statut:
ppublish
Résumé
Modern dermatotherapy is dominated by the development of various biologicals and small molecules. Janus kinase inhibitors (JAKi) form a novel class of small molecular synthetic compounds inhibiting the intracellular signal transduction of cytokine receptors. Cytokines are key mediators in the pathophysiology of numerous inflammatory skin diseases. Many cytokines use so-called type I and II cytokine receptors, which associate with the Janus kinases JAK1, JAK2, JAK3 or TYK2. JAKi are under clinical investigation for inflammatory skin disease, specifically in phase 3 trials for psoriasis or atopic dermatitis. Since JAKi are tested in oral as well as in topical formulations, they could become very popular in dermatotherapy. The mechanisms of JAKi, their selectivity, preliminary efficacy data, and their safety profile are discussed in this article.
Identifiants
pubmed: 31740978
doi: 10.1007/s00105-019-04509-x
pii: 10.1007/s00105-019-04509-x
doi:
Substances chimiques
Cytokines
0
Janus Kinase Inhibitors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
934-941Références
Immunol Rev. 2009 Mar;228(1):273-87
pubmed: 19290934
J Clin Lipidol. 2017 Sep - Oct;11(5):1243-1256
pubmed: 28751001
N Engl J Med. 2012 Aug 9;367(6):508-19
pubmed: 22873531
Mediators Inflamm. 2017;2017:6716419
pubmed: 29203970
J Allergy Clin Immunol. 2018 Aug;142(2):669-672.e7
pubmed: 29626572
J Cutan Med Surg. 2019 May/Jun;23(3):298-306
pubmed: 30902022
J Med Chem. 2019 Oct 24;62(20):8973-8995
pubmed: 31318208
J Exp Med. 2015 Sep 21;212(10):1641-62
pubmed: 26304966
J Invest Dermatol. 2014 Aug;134(8):2071-2074
pubmed: 25029321
Lancet. 2018 Jul 21;392(10143):222-231
pubmed: 30043749
Drugs. 2018 Oct;78(15):1527-1548
pubmed: 30238396
Arthritis Res Ther. 2015 Dec 15;17:362
pubmed: 26669566
N Engl J Med. 2018 Oct 4;379(14):1313-1321
pubmed: 30205746
Br J Dermatol. 2016 Nov;175(5):902-911
pubmed: 27423107
Fed Proc. 1966 Sep-Oct;25(5):1511-20
pubmed: 5332191
Exp Dermatol. 2014 Jan;23(1):7-11
pubmed: 24131352
J Invest Dermatol. 2016 Sep;136(9):1768-1780
pubmed: 27206704
J Invest Dermatol. 2014 Apr;134(4):992-1000
pubmed: 24213371
Eur J Immunol. 2017 Jul;47(7):1096-1107
pubmed: 28555727
Dermatol Ther. 2018 Nov;31(6):e12656
pubmed: 30264512
Lancet. 2019 Jan 26;393(10169):318-319
pubmed: 30696569
Nat Rev Rheumatol. 2017 Apr;13(4):234-243
pubmed: 28250461
N Engl J Med. 2019 Jul 18;381(3):291-293
pubmed: 31314977
Front Immunol. 2019 Jul 31;10:1808
pubmed: 31417572
J Immunol. 2011 Apr 1;186(7):4234-43
pubmed: 21383241
Immunol Rev. 2005 Feb;203:127-42
pubmed: 15661026
Annu Rev Med. 2015;66:311-28
pubmed: 25587654
Br J Dermatol. 2019 Oct 12;:null
pubmed: 31605536
Nat Immunol. 2009 Apr;10(4):356-60
pubmed: 19295632
Cell Chem Biol. 2016 Nov 17;23(11):1335-1340
pubmed: 27840070
J Am Acad Dermatol. 2017 Jun;76(6):1054-1060.e1
pubmed: 28390737
J Med Chem. 2018 Jun 28;61(12):5350-5366
pubmed: 29852068
J Am Acad Dermatol. 2017 Jul;77(1):79-87.e1
pubmed: 28396102
Drug Saf. 2018 Jul;41(7):645-653
pubmed: 29500799
Ann Rheum Dis. 2016 Oct;75(10):1843-7
pubmed: 27113415
JAMA Ophthalmol. 2018 Dec 1;136(12):1420-1422
pubmed: 30242383
J Am Acad Dermatol. 2012 Oct;67(4):658-64
pubmed: 22281165
Lancet. 2017 Jul 29;390(10093):457-468
pubmed: 28629665
Immunity. 2006 Nov;25(5):745-55
pubmed: 17088085
N Engl J Med. 2017 Oct 19;377(16):1525-1536
pubmed: 29045207
Science. 1995 Nov 3;270(5237):797-800
pubmed: 7481768
J Immunol. 2014 Jul 1;193(1):48-55
pubmed: 24890727
J Am Acad Dermatol. 2019 Apr;80(4):913-921.e9
pubmed: 29410014